biotech.today

Details

  • ●Modalities: small molecules
  • ●Therapeutic areas: oncology
  • ●Key targets: PI3Kα (mutant-selective), SHP2, GDC targets
  • ●Indications: HR+/HER2- metastatic breast cancer, solid tumors
  • ●Funding: $780M+ cash (end 2024)

Partners & investors

  • D.E. Shaw Research· Investor
  • Third Rock Ventures· Investor
  • SoftBank Vision Fund· Investor
  • GV (Google Ventures)· Investor

Key considerations

  • ●AI tools in use: Dynamo platform (proprietary), Cryo-EM structural biology, MD simulations, ML-guided compound design
  • ●D.E. Shaw Research co-founded (computational MD heritage)
  • ●Cryo-EM + AI protein dynamics = differentiated approach
  • ●Phase 3 readout expected ~2026-2027

Pipeline

  • Phase 11
  • Phase 31
Get live updates on Relay Therapeutics’s hiring, filings, and partnerships. Follow in BT Pro →
Source: Company website, SEC / Companies House filings, press releases, Crunchbase · biotech.today analysis (Apr 2026)

Key people

Sanjiv Patel

President & CEO

oncologyclinical developmentprecision medicine

Pat Dorsey

Chief Scientific Officer

computational chemistryprotein dynamicsdrug design
Visit website →LinkedIn →